{"generic":"Nesiritide","drugs":["Natrecor","Nesiritide"],"mono":{"0":{"id":"juzks0","title":"Generic Names","mono":"Nesiritide"},"1":{"id":"juzks1","title":"Dosing and Indications","sub":[{"id":"juzks1b4","title":"Adult Dosing","mono":"<ul><li><b>Congestive heart failure, Acutely decompensated - Dyspnea:<\/b> 2 mcg\/kg IV bolus followed by 0.01 mcg\/kg\/min continuous IV infusion; bolus may not be appropriate for patients with systolic blood pressure below 110 mmHg or if recently treated with afterload reducers; reduce dose or discontinue therapy if hypotension occurs; may restart at a 30% lower dose (no bolus) after the patient is stabilized<\/li><li><b>Congestive heart failure, Acutely decompensated - Dyspnea:<\/b> titration, may increase by 0.005 mcg\/kg\/min (after a bolus of 1 mcg\/kg IV) no more frequently than every 3 hours up to a MAX dose of 0.03 mcg\/kg\/min<\/li><\/ul>"},{"id":"juzks1b5","title":"Pediatric Dosing","mono":"safety and effectiveness not established in children "},{"id":"juzks1b6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment:<\/b> no dosage adjustment required<\/li><li><b>hypotension:<\/b> reduce dose or discontinue therapy; may restart at 30% reduced dose (no bolus) once patient is stable<\/li><\/ul>"},{"id":"juzks1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Congestive heart failure, Acutely decompensated - Dyspnea<br\/>"}]},"3":{"id":"juzks3","title":"Contraindications\/Warnings","sub":[{"id":"juzks3b9","title":"Contraindications","mono":"<ul><li>cardiogenic shock<\/li><li>hypersensitivity to nesiritide or any component of the product<\/li><li>systolic blood pressure less than 100 mmHg prior to therapy, persistent; increased risk of symptomatic hypotension<\/li><\/ul>"},{"id":"juzks3b10","title":"Precautions","mono":"<ul><li>cardiac output dependent upon venous return; use not recommended<\/li><li>cardiomyopathy, restrictive or obstructive; use not recommended<\/li><li>heart failure, severe, in which renal function may depend on the activity of the renin-angiotensin-aldosterone system; risk of azotemia<\/li><li>hypersensitivity\/allergic reactions, serious, have been reported; drug discontinuation recommended if reaction occurs<\/li><li>hypotension has been reported; dose reduction or drug discontinuation may be necessary<\/li><li>low cardiac filling pressures, suspected; use not recommended<\/li><li>pericardial tamponade; use not recommended<\/li><li>pericarditis, constrictive; use not recommended<\/li><li>renal function, decreased (increased serum creatinine), may occur; monitoring recommended<\/li><li>sensitivity to recombinant peptides, history; increased risk of hypersensitivity\/allergic reaction<\/li><li>valvular stenosis, significant; use not recommended<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"juzks3b11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"juzks3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"juzks4","title":"Drug Interactions","sub":{"2":{"id":"juzks4b15","title":"Moderate","mono":"<ul><li>Benazepril (probable)<\/li><li>Captopril (probable)<\/li><li>Cilazapril (probable)<\/li><li>Enalapril Maleate (probable)<\/li><li>Fosinopril (probable)<\/li><li>Lisinopril (probable)<\/li><li>Quinapril (probable)<\/li><li>Ramipril (probable)<\/li><li>Zofenopril (probable)<\/li><\/ul>"}}},"5":{"id":"juzks5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Hypotension (4% to 17%)<\/li><li><b>Gastrointestinal:<\/b>Nausea (3%)<\/li><li><b>Neurologic:<\/b>Dizziness (2%), Headache (7%)<\/li><li><b>Renal:<\/b>Serum creatinine raised (17% to 31.4%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Injection site extravasation<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction<\/li><li><b>Other:<\/b>Death, Increased risk<\/li><\/ul>"},"6":{"id":"juzks6","title":"Drug Name Info","sub":{"0":{"id":"juzks6b17","title":"US Trade Names","mono":"Natrecor<br\/>"},"2":{"id":"juzks6b19","title":"Class","mono":"<ul><li>Cardiovascular Agent<\/li><li>Natriuretic Peptide<\/li><\/ul>"},"3":{"id":"juzks6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"juzks6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"juzks7","title":"Mechanism Of Action","mono":"Systemic:  Human BNP increases intracellular concentrations of guanosine 3'5'-cyclic monophosphate (cGMP) and smooth muscle cell relaxation by binding to the particulate guanylate cyclase receptor of vascular smooth muscle and endothelial cells. Cyclic GMP serves as a second messenger to dilate veins and arteries. In human studies in patients with heart failure, nesiritide has been shown to reduce pulmonary capillary wedge pressure (in a dose-dependent manner) and systemic arterial pressure.<br\/>"},"8":{"id":"juzks8","title":"Pharmacokinetics","sub":{"1":{"id":"juzks8b24","title":"Distribution","mono":"Systemic: Vd: 0.19 L\/kg    <br\/>"},"3":{"id":"juzks8b26","title":"Excretion","mono":"Systemic: Renal<br\/>"},"4":{"id":"juzks8b27","title":"Elimination Half Life","mono":"Systemic: 18 min<br\/>"}}},"9":{"id":"juzks9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>for IV use only<br\/><\/li><li><b>Intravenous<\/b><br\/><ul><li>reconstitute vial (1.5 mg) by adding 5 mL of diluent (D5W, NS, or D5-0.45% NaCl) from a pre-filled 250 mL IV plastic bag and rock vial gently, do not shake; withdraw contents and add to 250 mL IV plastic bag (6 mcg\/mL)<\/li><li>use reconstituted solutions within 24 hours<\/li><li>prime IV tubing with an infusion of 5 mL of solution prior to connecting IV port or administering bolus or infusion<\/li><li>bolus must be drawn from the prepared infusion bag and administered over approximately 60 seconds through IV port in the tubing<\/li><li>following bolus, infuse at rate of 0.1 mL\/kg\/hr<\/li><li>flush catheter between administration of incompatible drugs<\/li><li>do not administer through a central heparin-coated catheter<\/li><\/ul><\/li><\/ul>"},"10":{"id":"juzks10","title":"Monitoring","mono":"<ul><li>reduced pulmonary capillary wedge pressure and improvement in short term (3 hours) symptoms of dyspnea are indicative of efficacy<\/li><li>serum creatinine; during and after completion of therapy; continue to monitor increased levels until stabilized<\/li><li>blood pressure; closely during administration<\/li><\/ul>"},"11":{"id":"juzks11","title":"How Supplied","mono":"<b>Natrecor<\/b><br\/>Intravenous Powder for Solution: 1.5 MG<br\/>"},"12":{"id":"juzks12","title":"Toxicology","sub":[{"id":"juzks12b31","title":"Clinical Effects","mono":"<b>NESIRITIDE<\/b><br\/>OVERDOSE: Information is limited. Excessive hypotension is the anticipated effect following overdose. ADVERSE EFFECTS: Hypotension, bradycardia, nausea and vomiting, insomnia, dizziness and anxiety occurred with greater frequency following nesiritide therapy during clinical trials as compared with patients in the control group.<br\/>"},{"id":"juzks12b32","title":"Treatment","mono":"<b>NESIRITIDE<\/b><br\/><ul><li>Support: Treatment is symptomatic and supportive. There is no known antidote available for overdose.<\/li><li>Hypotensive episode: IV 0.9% NaCl, dopamine, norepinephrine.<\/li><li>Monitoring of patient: Monitor vital signs and renal function.<\/li><\/ul>"},{"id":"juzks12b33","title":"Range of Toxicity","mono":"<b>NESIRITIDE<\/b><br\/>TOXICITY: A specific toxic dose has not been established. A 3-year-old child, with decompensated cardiac failure, received an 18-fold overdose of nesiritide (36 mcg\/kg) as an IV bolus dose. The patient did not develop any hemodynamic, cardiovascular or renal adverse effects following the overdose. THERAPEUTIC DOSE: The recommended adult dose is 2 mcg\/kg IV bolus followed by 0.01 mcg\/kg\/min continuous IV infusion.<br\/>"}]},"13":{"id":"juzks13","title":"Clinical Teaching","mono":"<ul><li>Drug may cause hypotension, headache, nausea, and back pain.<\/li><li>Instruct patient to report signs\/symptoms of hypotension.<\/li><\/ul>"}}}